Financial reports
10-Q
2024 Q1
Quarterly report
10 Apr 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
10-K
2023 FY
Annual report
15 Feb 24
10-Q
2023 Q3
Quarterly report
12 Oct 23
10-Q
2023 Q2
Quarterly report
13 Jul 23
10-Q
2023 Q1
Quarterly report
13 Apr 23
ARS
2022 FY
Annual report to shareholders
24 Mar 23
10-K
2022 FY
Annual report
9 Feb 23
10-Q
2022 Q3
Quarterly report
6 Oct 22
10-Q
2022 Q2
Quarterly report
7 Jul 22
Current reports
8-K
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
12 Apr 24
8-K
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
10 Apr 24
8-K
Other Events
9 Apr 24
8-K
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
11 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
8-K
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
1 Nov 23
8-K
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
12 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
S-8
Registration of securities for employees
15 Feb 24
S-8
Registration of securities for employees
9 Feb 23
POS AM
Prospectus update (post-effective amendment)
9 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
9 Feb 23
424B5
Prospectus supplement for primary offering
8 Jul 22
424B5
Prospectus supplement for primary offering
8 Jul 22
S-8
Registration of securities for employees
28 Jan 22
S-3ASR
Automatic shelf registration
4 Aug 21
Proxies
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
DEFA14A
Additional proxy soliciting materials
24 Mar 23
DEF 14A
Definitive proxy
24 Mar 23
DEFA14A
Additional proxy soliciting materials
25 Mar 22
DEF 14A
Definitive proxy
25 Mar 22
DEFA14A
Additional proxy soliciting materials
25 Mar 21
DEF 14A
Definitive proxy
25 Mar 21
Other
EFFECT
Notice of effectiveness
7 Apr 23
EFFECT
Notice of effectiveness
5 Mar 21
CORRESP
Correspondence with SEC
2 Mar 21
CORRESP
Correspondence with SEC
2 Mar 21
UPLOAD
Letter from SEC
1 Mar 21
EFFECT
Notice of effectiveness
24 Jul 20
CERT
Certification of approval for exchange listing
23 Jul 20
CORRESP
Correspondence with SEC
21 Jul 20
CORRESP
Correspondence with SEC
21 Jul 20
CORRESP
Correspondence with SEC
10 Jul 20
Ownership
4
Houte Hans van
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
4
Houte Hans van
15 Feb 24
4
Christine Ring
15 Feb 24
4
Gwenn Hansen
15 Feb 24
4
ARTHUR T SANDS
15 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24